Inhibition of sodium glucose cotransporter-2 affects HbA1c levels in people with insulin-dependent diabetes mellitus and differing levels of glucagon
We compared outcomes of several people with different prescriptions in an attempt to determine the effects of diabetes-related treatments on HbA1c levels. The first clinical case involved an 82-year-old Japanese female who received a total pancreatectomy 6 years ago because of an intraductal papillary mucinous neoplasm. She had not been diagnosed with diabetes mellitus before total pancreatectomy and was recently prescribed a sodium glucose cotransporter-2 inhibitor (SGLT2i; Ipragliflozin) at 50 mg/day in addition to insulin preparations.
Source: Primary Care Diabetes - Category: Primary Care Authors: Junichi Okada, Eijiro Yamada, Shuichi Okada, Masanobu Yamada Tags: Letter to the Editor Source Type: research
More News: Diabetes | Diabetes Mellitus | Endocrinology | Insulin | Japan Health | Primary Care | Sodium